Home

News:

Dr. Vuong Trieu, CEO, will be presenting the clinical study results titled “Non-inferiority of OT-101 (TGF-β2 Specific Inhibitor) versus Standard Chemotherapy in Glioma” on September 24th & 25th, 2018 at the 2018 American College of Clinical Pharmacology (ACCP) Annual Meeting in Bethesda, Maryland.

Learn More >>

Autotelic

Lipomedics